Sanofi asks to pull Tzield bid from FDA's controversial CNPV program: report

The FDA's Commissioner's National Priority Voucher program has been steeped in controversy since its inception. Now, Sanofi has asked that one of its applications be taken out of the fast-track program, according to Stat.

Читайте на сайте